Table 3 Cardiometabolic risk factors from baseline to end of study
Variable | Baseline for participants with follow-up data | End of study | Change for participants with follow-up dataa | 95% CI |
|---|---|---|---|---|
(n = 10) | (n = 10) | Â | Â | |
Glycemic status | ||||
 HbA1c (%) | 6.1(0.6) | 6.1(0.6) | − 0.04 (0.62) | − 0.5, 0.5 |
Anthropometry | ||||
 Weight (kg) | 77.1 (13.6) | 75.7 (13.0) | − 1.44 (2.29) | − 3.1, 0.2 |
 % change |  |  | − 2.0% |  |
Other cardiometabolic markers | ||||
 Systolic blood pressure (mmHg) | 134 (19.6) | 121 (9.0) | − 13 (14.6) | − 23.2, − 2.2 |
 Diastolic blood pressure (mmHg) | 82 (6.3) | 78 (7.5) | − 4 (5.0) | − 7.6, − 0.1 |
 Total cholesterol (mg/dl) | 169 (43.6) | 162.3 (33.3) | − 6.7 (25.1) | − 24.7, 11.3 |
 HDL (mg/dl) | 45.3 (22.5) | 45.8 (21.7) | 1.0 (6.7) | − 4.1, 5.1 |
 Triglycerides (mg/dl) | 204.5 (84.8) | 141.9 (62.8) | − 62.6 (84.7) | − 123.2, − 2.0 |